Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly (NYSE:LLY) announced Phase 3 ATTAIN-1 trial results for orforglipron, an investigational oral GLP-1 receptor agonist for obesity treatment. The once-daily pill demonstrated significant weight loss, with participants taking the highest dose (36mg) achieving an average reduction of 27.3 lbs (12.4%) at 72 weeks.
Key findings include: 59.6% of participants on the highest dose lost ≥10% body weight, 39.6% lost ≥15%, and among participants with prediabetes, up to 91% achieved near-normal blood sugar levels compared to 42% on placebo. The drug showed meaningful improvements in cardiovascular risk factors, reducing hsCRP levels by 47.7%.
Safety profile aligned with the GLP-1 class, with primarily gastrointestinal-related adverse events. Lilly plans global regulatory submissions for obesity treatment, with potential approval as early as next year, followed by type 2 diabetes submission in 2026.
Eli Lilly (NYSE:LLY) has announced plans to construct a $5 billion manufacturing facility in Goochland County, Virginia, marking the first of four planned U.S. manufacturing sites to be announced this year. The facility will be the company's first dedicated, fully integrated site for producing active pharmaceutical ingredients (API) and drug products for bioconjugates and monoclonal antibodies.
The project will create 650 high-paying permanent jobs and 1,800 construction jobs, with completion expected within five years. The facility will focus on manufacturing antibody-drug conjugates (ADCs) and is part of Lilly's $50 billion U.S. capital expansion commitment since 2020. For every dollar invested, the company expects to generate up to four dollars in local economic activity.
Eli Lilly (NYSE:LLY) announced its participation in Bernstein's 2nd Annual Healthcare Forum on September 25, 2025. The company's CFO, Lucas Montarce, will participate in a fireside chat at 8:00 AM ET.
Investors can access a live audio webcast through Lilly's investor website, with a replay available for approximately 90 days following the event.
Eli Lilly (NYSE:LLY) has launched "Brain Health Matters," a global campaign aimed at promoting proactive brain health and early detection of Alzheimer's disease. The company has partnered with acclaimed actress Julianne Moore to raise awareness, particularly among women who represent nearly two-thirds of Alzheimer's diagnoses.
The multi-year campaign builds on 35 years of brain health research and comes as statistics show that 13.8 million people aged 65 and older are projected to have Alzheimer's dementia by 2060. The initiative emphasizes early intervention, noting that Alzheimer's can begin up to 20 years before symptoms appear. The campaign will run across U.S. television, digital, and audio platforms, with plans for global expansion.
Eli Lilly (NYSE:LLY) has launched Lilly TuneLab, an AI/ML platform providing biotech companies access to drug discovery models trained on Lilly's extensive research data valued at over $1 billion. The platform, part of Lilly Catalyze360's offerings, employs federated learning to allow biotechs to utilize Lilly's AI capabilities while protecting proprietary data.
The platform is trained on comprehensive datasets including drug disposition, safety, and preclinical data from hundreds of thousands of unique molecules. Partner companies will contribute training data to continuously improve the ecosystem. Future releases will include in vivo small molecule predictive models available exclusively on TuneLab.
Eli Lilly (NYSE:LLY) announced positive topline results from its Phase 3 BRUIN CLL-313 trial of Jaypirca (pirtobrutinib) in treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study demonstrated statistically significant improvement in progression-free survival compared to chemoimmunotherapy in treatment-naïve patients.
The trial achieved its primary endpoint with one of the most compelling effect sizes observed for a single-agent BTK inhibitor in front-line CLL studies. While overall survival data is not yet mature, it shows strong positive trends. This marks Jaypirca's third positive Phase 3 study, with global regulatory submissions for label expansions planned to begin in late 2025.
Eli Lilly (NYSE:LLY) announced that its drug olomorasib has received FDA Breakthrough Therapy designation for first-line treatment of certain metastatic non-small cell lung cancer (NSCLC) patients. The designation applies to olomorasib in combination with KEYTRUDA for patients with unresectable advanced or metastatic NSCLC with KRAS G12C mutation and PD-L1 expression ≥ 50%.
The designation is based on promising results from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial. Olomorasib is described as a potent and selective second-generation KRAS G12C inhibitor with preliminary evidence of central nervous system activity. Updated efficacy and safety data will be presented at the upcoming IASLC 2025 World Conference on Lung Cancer in Barcelona, featuring integrated analyses from multiple clinical trials.
Eli Lilly (NYSE:LLY) announced significant positive results from its Phase 3 monarchE trial for Verzenio, its treatment for HR+, HER2-, node-positive, high-risk early breast cancer. The study demonstrated that two years of Verzenio plus endocrine therapy achieved a statistically significant improvement in overall survival compared to endocrine therapy alone.
The seven-year landmark analysis revealed sustained benefits in both invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS). The safety profile remained consistent with previous reports, with all patients having completed or discontinued the two-year treatment course. These results establish Verzenio as the standard of care for this high-risk breast cancer patient population.
Eli Lilly (NYSE:LLY) announced positive Phase 3 ATTAIN-2 trial results for orforglipron, its investigational oral GLP-1 receptor agonist for obesity and type 2 diabetes treatment. The highest dose (36mg) achieved significant weight loss of 22.9 lbs (10.5%) compared to placebo's 5.1 lbs (2.2%) at 72 weeks.
Key achievements include A1C reductions of 1.3% to 1.8% from a baseline of 8.1%, with 75% of participants reaching A1C ≤6.5%. The drug demonstrated improvements in cardiovascular risk factors and reduced inflammation markers by 50.6%. The safety profile aligned with injectable GLP-1 medicines, with primarily mild-to-moderate gastrointestinal side effects.
Following these successful results, Lilly plans to initiate global regulatory submissions for orforglipron's approval as a once-daily oral treatment.
Eli Lilly (NYSE:LLY) has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The company will be represented by Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D., Lilly chief medical officer, who will participate in a fireside chat at 9:15 a.m. ET.
Investors can access a live audio webcast of the presentation through Lilly's investor website, with a replay available for approximately 90 days following the event.